Spotlight Pathology Gets EHE Backing for Faster Cancer Diagnosis

Spotlight Pathology, a Manchester-based MedTech company, has secured £425,000 in an investment round led by EHE Ventures. The funding aims to bolster the development of an AI-powered pathology platform designed to expedite and improve the accuracy of blood cancer diagnoses. The current funding is a component of a broader £1.1 million investment target, which is anticipated to conclude in the coming months. This larger financing includes a significant commitment from EHE Ventures' AI Growth Fund, alongside contributions from DeepBridge Capital and Lyva Labs. Spotlight Pathology is working on solutions for faster diagnosis of lymphoma and leukaemia through AI-driven technology. Its platform leverages advanced computer vision models, trained on UK hospital datasets, to streamline the diagnostic process for lymph node and bone marrow biopsies. The funding will facilitate the completion of their AI platform, secure regulatory approvals, and enable pilot program launches in the UK, Europe, and the US. EHE Ventures, known for supporting mission-driven, AI-utilizing startups, will provide more than capital by offering guidance through their Venture Studio to aid in scaling and market preparation. Dr. Sam Perona, CEO of Spotlight Pathology, emphasizes the urgency in improving diagnostic workflows due to a critical pathologist shortage, highlighting the potential impact on patient treatment timelines.